Non-peptide

ERR agonist class (SLU-PP family)

Also known as

SLU-PP-332 · SLU-PP-915 · SLU-PP class · SLU PP class · ERR agonists · ERR pan-agonists · pan-ERR agonists · exercise mimetic discussion class · Saint Louis University PP series · Burris lab ERR agonists

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Experimental ERR-agonist family	SLU-PP-332 and SLU-PP-915 are different non-peptide molecules discussed for easier cardio, endurance and fat loss. Estrogen-related receptor activity is not estrogen replacement.
Route and identity	Preclinical work reports poor oral availability for 332 and oral activity for 915 in mice. That does not measure absorption of a particular human capsule or make the compounds interchangeable.

Notes

The SLU-PP family contains experimental small molecules discussed for easier cardio, endurance and fat loss. SLU-PP-332 and SLU-PP-915 activate estrogen-related receptors, but they are different compounds. Reports range from noticeably easier training to no benefit, fatigue or disturbed sleep; human performance and safety remain uncertain.

A class, not one oral product. ERRs regulate energy-use genes. Despite their name, activating these receptors is not estrogen replacement. The SLU-PP compounds are non-peptide research molecules; shared targets do not make 332 and 915 interchangeable. Billon et al.: synthetic ERR agonist and mouse exercise capacity (Animal context · Accessed 2026-09-30)

Why the route argument matters. Bioavailability means how much reaches circulation. The developing lab reports that 332 lacks oral bioavailability in its preclinical work; chemically distinct 915 showed oral activity in mice. Neither statement measures absorption of a particular human capsule. Billon et al.: orally active SLU-PP-915 (Animal context · Accessed 2026-09-30)

Source context — Billon et al.: synthetic ERR agonist and mouse exercise capacity: Only abstract body inspected in this turn; no full-paper numerical reanalysis or human inference.

Source context — Billon et al.: orally active SLU-PP-915: Abstract only; current PubMed open showed a minimal page and publisher403. No human absorption, efficacy or safety conclusion. Full-text numerical PK not reverified.

What people notice

Easier cardio	One oral-332 contributor describes faster bike work at lower heart rate and easier training over weeks, without an obvious stimulant rush.
Appearance claims	The same person notices more definition around week four. Diet, training and other agents complicate fat-loss claims; tracker calories do not directly measure fat burned.
No benefit or fatigue	Other accounts describe no benefit, poor sleep or marked lethargy. A lower exercise pulse can coexist with fatigue rather than demonstrating better fitness.

Notes

Cardio that feels less demanding. One oral-332 contributor describes faster stationary-bike work at lower heart rate and easier cardio over subsequent weeks. The appeal can be less perceived fatigue without an obvious stimulant rush. SLU-PP-332: stopping, onset and an eight-week oral account (Community discussion · Accessed 2026-09-30)

Leaner appearance is a separate claim. That contributor noticed definition around week four. Diet, training and other agents complicate fat-loss accounts; wearable calorie estimates do not directly measure extra fat burned. SLU-PP-332: stopping, onset and an eight-week oral account (Community discussion · Accessed 2026-09-30)

Higher amounts do not reliably rescue results. An Eroids contributor preferred 500 mcg capsules but felt nothing from 25 mg tablets. Another reports little benefit and poor sleep at 40 mg/day orally. Product identity remains unverified; this is disagreement, not proof of counterfeits. Dosing experience with SLU PP332? (Community discussion · Accessed 2026-09-30)

Less sweat and lower exercise heart rate also appear. A 332 user describes both with marked lethargy, contrary to warmth-and-sweat narratives. The proposed NAD+ explanation is speculation. Neither a lower exercise pulse nor a higher resting pulse independently proves better fitness or metabolic benefit. Lethargy and lower exercise heart rate on SLU-PP-332 (Personal report · Accessed 2026-09-30)

Source context — SLU-PP-332: stopping, onset and an eight-week oral account: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics.

Source context — Dosing experience with SLU PP332?: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics. Forum has vendor/promotion badges. Unstated routes not inferred; no grapefruit absorption advice adopted.

Source context — Lethargy and lower exercise heart rate on SLU-PP-332: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics. NAD+ improvement does not verify a mechanism or remedy.

Doses people talk about

Oral 332 claims	Discussion spans 250–500 mcg/day capsules, multi-mg amounts, 20–100 mg/day talk and 100–400 mg outliers. These conflicting claims are not one useful dose range.
Injected 332 claims	Preserved under-the-skin discussion includes 250–500 mcg/day, 500 mcg–1.5 mg/day and 1.25–2.5 mg/day, sometimes divided two or three times daily. 500 mcg equals 0.5 mg.
Oral 915 log	One author records 10 mg each morning, later 20 mg, then 30 mg/day without an established outcome. Earlier 2 mg-is-high and about 100 mg suggestions remain competing claims, not equivalent exposures.
Misidentified amounts	A 915-titled thread includes tablet amounts later redirected to 332 or left unclear. Its 20 mg/day and 30 mg morning-plus-noon examples cannot establish a 915 dose.

Notes

Oral 332: micrograms and milligrams conflict. The original discussion spans 250–500 mcg/day capsules, multi-mg amounts, 20–100 mg/day talk and 100–400 mg outliers. These are separate claims, not one useful dose range. One opened commenter reports 400 mg/day; that establishes only the claim. Liquid SLU-PP-915 versus 332 (Community discussion · Accessed 2026-09-30)

Injected 332: different totals. Preserved SubQ discussion includes 250–500 mcg/day, a 500 mcg–1.5 mg/day cluster and 1.25–2.5 mg/day accounts, sometimes split two or three times daily. Here 500 mcg equals 0.5 mg.

Oral 915: an actual capsule log. One author records 10 mg each morning, later 20 mg, then 30 mg/day; no outcome is established. Earlier 2 mg-is-high and approximately 100 mg suggestions remain competing discussion, not equivalent exposure or validated amounts. SLU-PP-915 personal experiment (Personal report · Accessed 2026-09-30)

Some purported 915 amounts are misidentified. The 915-titled Reddit thread includes a 20 mg tablet daily with BAM15 and 30 mg morning plus noon, totaling 60 mg/day. Replies redirect the discussion to 332; the latter molecule remains insufficiently specified. These cannot establish a 915 dose. SLU-PP-915 thread with molecule and trial corrections (Community discussion · Accessed 2026-09-30)

Source context — Liquid SLU-PP-915 versus 332: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics. Search-only later capsule comments excluded; no date inferred from cached relative timestamps.

Source context — SLU-PP-915 personal experiment: One person's unverified pills; retatrutide and SANA co-use; dose documentation is not evidence of benefit. Page may change.

Source context — SLU-PP-915 thread with molecule and trial corrections: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics. Thread heading alone cannot establish molecule; fatigue and longer recovery appear despite initial 'nil side effects' wording.

Half-life, onset & duration

Felt onset	One injected-332 account describes less fatigue on day one. A separate oral-332 author notes a bike difference on day four and easier cardio around week three. Same-day nulls also occur.
Felt duration	Neither molecule has a dependable hours-per-dose window here. One eight-week 332 user lost the effortless-cardio feeling after stopping without a crash; other crash stories remain disputed.
Half-life	For 332, 1.5-hour and about 10-hour forum claims lack human measurements; other vendor values also conflict. Human 915 half-life is not established here. Mouse timings cannot fill that gap.

Notes

Same-day sensations are inconsistent. An injectable-332 log describes reduced fatigue on day one. Preserved SubQ reports describe warmth or flushing around 20–60 minutes, alongside same-day nulls. A liquid-915 poster calls energy immediate but supplies neither exact minutes nor milligrams. My SLU-PP-332 Log / Experience (Personal report · Accessed 2026-09-30) · Liquid SLU-PP-915 versus 332 (Community discussion · Accessed 2026-09-30)

Performance and appearance have later checkpoints. The 500 mcg/day oral-332 contributor noticed a bike difference on day four, easier cardio around three weeks and definition around four. Those are one person's observations, not an expected sequence for this class. SLU-PP-332: stopping, onset and an eight-week oral account (Community discussion · Accessed 2026-09-30)

No dependable hours-per-dose window. Neither molecule has a consistent human felt-duration interval in these accounts. One 332 poster was exhausted by 10 am after 6:30–7 am use; route and amount were unstated. Lethargy and lower exercise heart rate on SLU-PP-332 (Personal report · Accessed 2026-09-30) · Liquid SLU-PP-915 versus 332 (Community discussion · Accessed 2026-09-30)

After stopping also varies. An eight-week oral-332 user reported no crash but lost the effortless-cardio feeling. The same thread raises a secondhand prolonged-crash story with disputed alternative explanations. It cannot establish withdrawal frequency or a recovery deadline. SLU-PP-332: stopping, onset and an eight-week oral account (Community discussion · Accessed 2026-09-30)

332: 1.5 hours versus about 10 hours. A sublingual-332 commenter asserts 1.5 hours; an Eroids commenter guesses about 10. Neither supplies human pharmacokinetic measurements. The preserved record also contains 1–2-hour, 3–6-hour and 12–16-hour vendor/forum claims; do not average them. SLU-PP-915? Anyone heard of this or tried it? (Secondhand community claim · Accessed 2026-09-30) · Dosing experience with SLU PP332? (Community discussion · Accessed 2026-09-30)

915: no established human half-life here. The inspected human discussions do not measure clearance. Short mouse plasma figures circulating in comparisons belong to animal context below, not a human capsule estimate. Felt energy cannot supply the missing number. Liquid SLU-PP-915 versus 332 (Community discussion · Accessed 2026-09-30) · SLU-PP-915 thread with molecule and trial corrections (Community discussion · Accessed 2026-09-30)

Previously recorded mouse timing stays mouse timing. The frozen timing record gives oral-915 plasma half-life of 18–28 minutes in mice. For 332 it records sampling at two and six hours after 30 mg/kg intraperitoneally. Those samples are not a half-life. The 915 full text was inaccessible during the recorded review. Previously source-bound SLU-PP mouse timing measurements (Animal context · Accessed 2026-09-30)

Source context — My SLU-PP-332 Log / Experience: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics. Anabolic-steroid co-use and vendor praise; only page1 inspected, not later pages. Tracker calories are estimates.

Source context — SLU-PP-915? Anyone heard of this or tried it?: Unverified self-experiments, product identity and other substances; no controlled attribution, prevalence estimate or measured human pharmacokinetics. Source of half-life assertion absent; no human measurement or route conversion.

Source context — Previously source-bound SLU-PP mouse timing measurements: Exact original record reviewed, not fresh full-text verification. Current publisher403. Species, molecule and routes remain explicit; not a source for community practical sections.

Cycles people discuss

Reported blocks	2–4-week experiments, 4–8-week blocks and some 8–12-week runs appear; one oral-332 account lasted eight weeks. Open-ended cutting use also appears.
Breaks disagree	Patterns include 1–2 weeks off, equal 4–8-week breaks and five days on/two off. No validated tolerance-reset, taper or washout schedule follows.

Notes

Two to eight weeks is convention. The original record contains 2–4-week experiments, 4–8-week blocks and some 8–12-week runs. One oral account lasted eight weeks. Open-ended cutting/prep use also appears; duration of use is not evidence of long-term safety. SLU-PP-332: stopping, onset and an eight-week oral account (Community discussion · Accessed 2026-09-30)

Break schedules disagree. Preserved patterns include 1–2 weeks off, equal-length 4–8-week breaks and five days on/two off. One injectable log changed to weekdays during week six. No validated tolerance-reset, taper or washout schedule follows. My SLU-PP-332 Log / Experience (Personal report · Accessed 2026-09-30)

Stacks

Metabolic combinations	5-Amino-1MQ, sometimes with MOTS-c, is named alongside the class. GLP-1 combinations include semaglutide, tirzepatide or retatrutide, without established combined benefit or safety.
Other co-use	Cardarine, BAM15, caffeine or other stimulants appear; NAD-related supplements are also listed. These combinations cannot isolate an ERR effect.
332 versus 915	Switching from oral 332 to 915 is a sequential story, not a validated conversion. Combining both adds unknown exposure rather than demonstrated benefit.

Notes

Top dual (332 culture): SLU-PP-332 + 5-Amino-1MQ — most-named pairing (ERR oxidative program + NNMT / NAD-adjacent metabolic talk). [community]

Triple metabolic: SLU + 5-Amino-1MQ + MOTS-c appears in synergy write-ups (mitochondrial / AMPK adjacency); attribution gets muddy fast. [community]

GLP-1 era stacks: Semaglutide / tirzepatide / retatrutide for appetite deficit + SLU class for “oxidative tone / muscle fuel” theory — no published combo safety or synergy data. [community]

Endurance adjacency: Cardarine (GW501516) / other “exercise mimetic” PPARδ talk sits next to ERR threads; cardarine carries its own rodent carcinogenicity / WADA history. [community]

NAD support chatter: NMN, NR, NAD+, urolithin A sometimes listed alongside mitochondrial-leaning stacks. [community]

Cut confounds: Caffeine, yohimbine-class stims, AOD-9604, SARMs — multi-agent logs cannot isolate ERR effect. [community]

BAM15 / uncoupler talk: Occasional advanced pairing with mitochondrial uncouplers — risk stacking, not mainstream. [community]

A 915 heading can hide a 332 story. The early thread's tablet/BAM15 account describes endurance and focus alongside slower recovery, lunchtime sleepiness and tendon discomfort. A separate trial claim was explicitly corrected to ATX-304. Read replies before treating either as 915 evidence. SLU-PP-915 thread with molecule and trial corrections (Community discussion · Accessed 2026-09-30)

332 vs 915 choice, not stack: Common plan is inject 332 or oral 915, not both. Dual pan-ERR same-day is speculative risk stacking. [community]

Failed oral 332 → 915 switch: Sequential narrative path after null oral-332 runs. [anecdote]

Combinations add unknowns. Discussion includes 5-Amino-1MQ, MOTS-c, GLP-1 drugs, stimulants and BAM15. Neither synergy nor safety follows from those stacks, and combining 332 with 915 adds unresolved exposure. Persistent adverse symptoms should not be normalized as adaptation. SLU-PP-915 thread with molecule and trial corrections (Community discussion · Accessed 2026-09-30)

Watch for

Fatigue, sleep and heart rate	One injected-332 log describes afternoon crashes, poor sleep and resting heart rate at 95–105 bpm, alongside steroid use. Other reports include sweating, flushing, anxiety, shakes, stomach upset or more hunger.
Units and product identity	mcg versus mg is a thousandfold change; 250 mcg versus 25 mg is one hundredfold. Unverified labels cannot establish actual amount or molecule.
Mistaken 915 stories	One 915-heading account actually names 332, and a purported human-trial claim was corrected to ATX-304. Titles alone cannot identify the compound or validate its outcome.

Notes

Fatigue, sleep and heart-rate changes matter. One injectable-332 log developed afternoon crashes and poor sleep, with resting heart rate later reported at 95–105 bpm. Steroid co-use prevents attribution. Preserved accounts also include sweating, flushing, stomach upset, anxiety, shakes and increased hunger. My SLU-PP-332 Log / Experience (Personal report · Accessed 2026-09-30)

Feeling nothing does not settle product identity. Unverified capsules, powders and injections may differ in identity or amount. A unit change from mcg to mg is a thousandfold change; 250 mcg versus 25 mg differs one hundredfold. A stronger label is not proof of stronger exposure.

Full notes

What the SLU-PP family is

A class, not one oral product. ERRs regulate energy-use genes. Despite their name, activating these receptors is not estrogen replacement. The SLU-PP compounds are non-peptide research molecules; shared targets do not make 332 and 915 interchangeable. Animal context Community
Why the route argument matters. Bioavailability means how much reaches circulation. The developing lab reports that 332 lacks oral bioavailability in its preclinical work; chemically distinct 915 showed oral activity in mice. Neither statement measures absorption of a particular human capsule. Animal context

What people hope to notice

Cardio that feels less demanding. One oral-332 contributor describes faster stationary-bike work at lower heart rate and easier cardio over subsequent weeks. The appeal can be less perceived fatigue without an obvious stimulant rush. Reddit
Leaner appearance is a separate claim. That contributor noticed definition around week four. Diet, training and other agents complicate fat-loss accounts; wearable calorie estimates do not directly measure extra fat burned. Reddit Community

Doses people discuss

Oral 332: micrograms and milligrams conflict. The original discussion spans 250–500 mcg/day capsules, multi-mg amounts, 20–100 mg/day talk and 100–400 mg outliers. These are separate claims, not one useful dose range. One opened commenter reports 400 mg/day; that establishes only the claim. Community Reddit
Injected 332: different totals. Preserved SubQ discussion includes 250–500 mcg/day, a 500 mcg–1.5 mg/day cluster and 1.25–2.5 mg/day accounts, sometimes split two or three times daily. Here 500 mcg equals 0.5 mg. Community
Oral 915: an actual capsule log. One author records 10 mg each morning, later 20 mg, then 30 mg/day; no outcome is established. Earlier 2 mg-is-high and approximately 100 mg suggestions remain competing discussion, not equivalent exposure or validated amounts. Personal report Community
Some purported 915 amounts are misidentified. The 915-titled Reddit thread includes a 20 mg tablet daily with BAM15 and 30 mg morning plus noon, totaling 60 mg/day. Replies redirect the discussion to 332; the latter molecule remains insufficiently specified. These cannot establish a 915 dose. Reddit

Half-life claims and their origins

332: 1.5 hours versus about 10 hours. A sublingual-332 commenter asserts 1.5 hours; an Eroids commenter guesses about 10. Neither supplies human pharmacokinetic measurements. The preserved record also contains 1–2-hour, 3–6-hour and 12–16-hour vendor/forum claims; do not average them. Canadian Brawn Eroids Community
915: no established human half-life here. The inspected human discussions do not measure clearance. Short mouse plasma figures circulating in comparisons belong to animal context below, not a human capsule estimate. Felt energy cannot supply the missing number. Reddit Reddit

When people notice a change

Same-day sensations are inconsistent. An injectable-332 log describes reduced fatigue on day one. Preserved SubQ reports describe warmth or flushing around 20–60 minutes, alongside same-day nulls. A liquid-915 poster calls energy immediate but supplies neither exact minutes nor milligrams. Personal report Community Reddit
Performance and appearance have later checkpoints. The 500 mcg/day oral-332 contributor noticed a bike difference on day four, easier cardio around three weeks and definition around four. Those are one person's observations, not an expected sequence for this class. Reddit

How long it feels noticeable

No dependable hours-per-dose window. Neither molecule has a consistent human felt-duration interval in these accounts. One 332 poster was exhausted by 10 am after 6:30–7 am use; route and amount were unstated. Personal report Reddit
After stopping also varies. An eight-week oral-332 user reported no crash but lost the effortless-cardio feeling. The same thread raises a secondhand prolonged-crash story with disputed alternative explanations. It cannot establish withdrawal frequency or a recovery deadline. Reddit

Courses and breaks in discussion

Two to eight weeks is convention. The original record contains 2–4-week experiments, 4–8-week blocks and some 8–12-week runs. One oral account lasted eight weeks. Open-ended cutting/prep use also appears; duration of use is not evidence of long-term safety. Community Reddit
Break schedules disagree. Preserved patterns include 1–2 weeks off, equal-length 4–8-week breaks and five days on/two off. One injectable log changed to weekdays during week six. No validated tolerance-reset, taper or washout schedule follows. Community Personal report

Cautions that change the picture

Fatigue, sleep and heart-rate changes matter. One injectable-332 log developed afternoon crashes and poor sleep, with resting heart rate later reported at 95–105 bpm. Steroid co-use prevents attribution. Preserved accounts also include sweating, flushing, stomach upset, anxiety, shakes and increased hunger. Personal report Community
Feeling nothing does not settle product identity. Unverified capsules, powders and injections may differ in identity or amount. A unit change from mcg to mg is a thousandfold change; 250 mcg versus 25 mg differs one hundredfold. A stronger label is not proof of stronger exposure. Community
Combinations add unknowns. Discussion includes 5-Amino-1MQ, MOTS-c, GLP-1 drugs, stimulants and BAM15. Neither synergy nor safety follows from those stacks, and combining 332 with 915 adds unresolved exposure. Persistent adverse symptoms should not be normalized as adaptation. Community Community Reddit

What community accounts add

Higher amounts do not reliably rescue results. An Eroids contributor preferred 500 mcg capsules but felt nothing from 25 mg tablets. Another reports little benefit and poor sleep at 40 mg/day orally. Product identity remains unverified; this is disagreement, not proof of counterfeits. Eroids
Less sweat and lower exercise heart rate also appear. A 332 user describes both with marked lethargy, contrary to warmth-and-sweat narratives. The proposed NAD+ explanation is speculation. Neither a lower exercise pulse nor a higher resting pulse independently proves better fitness or metabolic benefit. Personal report Community
A 915 heading can hide a 332 story. The early thread's tablet/BAM15 account describes endurance and focus alongside slower recovery, lunchtime sleepiness and tendon discomfort. A separate trial claim was explicitly corrected to ATX-304. Read replies before treating either as 915 evidence. Reddit
New 915 interest is ahead of clear outcomes. The liquid poster reports stimulation but cannot yet assess weight loss. Switching after a null oral-332 run recurs in discussion, not as a validated conversion. Claims that 915 is twice as bioavailable or universally stronger are not human comparisons. Reddit Reddit Community

Animal findings: separate context

Exercise-related biology, not a human protocol. Cell and mouse experiments support ERR activity and increased endurance; oral 915 retained exercise-capacity effects after adjusting for exposure. These results do not establish human route equivalence or replace training. Animal context Animal context
Previously recorded mouse timing stays mouse timing. The frozen timing record gives oral-915 plasma half-life of 18–28 minutes in mice. For 332 it records sampling at two and six hours after 30 mg/kg intraperitoneally. Those samples are not a half-life. The 915 full text was inaccessible during the recorded review. Animal context